Camizestrant

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Camizestrant, sold under the brand name Etcamah, is an anti-cancer medication used for the treatment of breast cancer. It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD). Camizestrant is an oral selective estrogen receptor degrader (ngSERD) and complete estrogen receptor (ER) antagonist.

It blocks the activity of estrogen receptor alpha encoded by both wild-type and mutated ESR1 and induces proteasome-dependent degradation of estrogen receptor alpha, without agonizing estrogen receptor alpha. Camizestrant was authorized for medical use in the European Union in July 2026, and in the United States in September 2026.

Camizestrant, sold under the brand name Etcamah, is an anti-cancer medication used for the treatment of breast cancer. It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD). Camizestrant is an oral selective estrogen receptor degrader (ngSERD) and complete estrogen receptor (ER) antagonist.

It blocks the activity of estrogen receptor alpha encoded by both wild-type and mutated ESR1 and induces proteasome-dependent degradation of estrogen receptor alpha, without agonizing estrogen receptor alpha. Camizestrant was authorized for medical use in the European Union in July 2026, and in the United States in September 2026.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378612549 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.